CAJ | 학술논문

目的探讨皮肤划痕症患者经抗组胺药物治疗后组胺及氧化活性水平.方法 85例皮肤划痕症患者给予地氯雷他定或西替利嗪治疗4周,在治疗前后用ELISA检测血中组胺含量以及血清超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-PX)、丙二醛(MDA)含量,并与正常对照组相比,同时观察药物疗效.结果地氯雷他定和西替利嗪治疗皮肤划痕症的有效率分别为83.72%和78.57%,两组疗效差异无统计学意义(x2=0.369,P>0.05).皮肤划痕症患者治疗前血中组胺(3.87±1.21)高于正常人对照组(1.76±0.56,P<0.05);SOD(86.29±19.9),GSH-PX(74.52±47.67)活性低于对照组(SOD 112.12±27.88,GSH-PX 915.06±115.96,P<0.05),MDA(3.86±1.03)高于对照组(2.19±0.82,P<0.05).患者组治疗后组胺水平降低(1.61±0.47,P<0.05),SOD变化差异无统计学意义,GSH-PX(921.46±157.37)活性增高(P<0.05),MDA(2.65±0.77)含量下降(P<0.05).结论皮肤划痕症患者血中组胺含量增高,存在氧化一抗氧化失衡.地氯雷他定与西替利嗪治疗有效.
목적 탐토피부화흔증환자경항조알약물치료후조알급양화활성수평.방법 85례피부화흔증환자급여지록뢰타정혹서체리진치료4주,재치료전후용ELISA검측혈중조알함량이급혈청초양화물기화매(SOD)、곡광감태과양화물매(GSH-PX)、병이철(MDA)함량,병여정상대조조상비,동시관찰약물료효.결과 지록뢰타정화서체리진치료피부화흔증적유효솔분별위83.72%화78.57%,량조료효차이무통계학의의(x2=0.369,P>0.05).피부화흔증환자치료전혈중조알(3.87±1.21)고우정상인대조조(1.76±0.56,P<0.05);SOD(86.29±19.9),GSH-PX(74.52±47.67)활성저우대조조(SOD 112.12±27.88,GSH-PX 915.06±115.96,P<0.05),MDA(3.86±1.03)고우대조조(2.19±0.82,P<0.05).환자조치료후조알수평강저(1.61±0.47,P<0.05),SOD변화차이무통계학의의,GSH-PX(921.46±157.37)활성증고(P<0.05),MDA(2.65±0.77)함량하강(P<0.05).결론 피부화흔증환자혈중조알함량증고,존재양화일항양화실형.지록뢰타정여서체리진치료유효.
Objective To determine the levels of plasma histamine and oxidative status in patients with dermatographism before and after the treatment with anti-histamine drugs. Methods Totally, 85 patients with dermatographism were randomly divided into two groups to receive oral desloratadine and cetirizine respectively for 4 weeks. Enzyme linked immunosorbent assay (ELISA) was performed to detect the plasma level of histamine, superoxide dismutases (SOD), glutathion peroxidase (GSH-PX) and malondialdehyde (MDA) in all the patients before and after the treatment and in 15 normal human controls. The efficacy of desloratadine and cetirizine for dermatographism was estimated. Results The response rate was 83.72% and 78.57% in patients treated with desloratadine and those with cetirizine, respectively (x2 = 0.369, P> 0.05). The untreated patients with dermatographism showed an elevation in the plasma level of histamine (3.87 ± 1.21 ng/ml vs. 1.76 ± 0.56 ng/ml, P< 0.05) and MDA (3.86 ± 1.03 nmol/ml vs. 2.19 ± 0.82 nmol/ml, P< 0.05), but a decline in the activity of SOD (86.29 ± 19.9 U/ml vs. 112.12 ± 27.88 U/ml, P< 0.05) and GSH-PX (74.52 ± 47.67 vs.915.06 ± 115.96, P< 0.05) compared with the normal human controls. The treatment with antihistamine induced a reduction in the plasma level of histamine (1.61 ± 0.47 ng/ml vs. 3.87 ± 1.21 ng/ml, P< 0.05) and MDA (2.65 ± 0.77 nmol/ml vs. 3.86 ± 1.03 nmol/ml, P< 0.05), but an increment in the activity of GSH-PX (921.46 ± 157.37 vs.74.52 ± 47.67, P < 0.05) with no changes of SOD in patients with dermatographism. Conclusions In patients with dermatographism, plasma histamine is increased and there is an imbalance of oxidation-antioxidation.Desloratadine and cetirizine are effective for the treatment of dermatographism.